Studies have shown that TACC3 is highly expressed in lung cancer (Ha et al., 2015), bladder cancer (Wang et al., 2011), multiple myeloma (Stewart et al., 2004), osteosarcoma (Matsuda et al., 2018), prostate cancer (Li et al., 2017), glioblastoma (Singh et al., 2012), ovarian cancer (Lauffart et al., 2005), and colorectal cancer (Du et al., 2016). Here, TACC3 is linked to urinary bladder carcinoma.